Please login to the form below

Not currently logged in
Email:
Password:

EU approves Janssen's prostate cancer drug

The European Commission has approved Janssen-Cilag's Zytiga, a treatment for metastatic castration-resistant prostate cancer (mCRPC)

Janssen-Cilag has announced that the European Commission (EC) has approved its late stage prostate cancer drug Zytiga (abiraterone acetate) for marketing. The approval follows an accelerated regulatory review process by the European Medicines Agency (EMA) and a positive opinion from the Committee for Medicinal Products for Human Use (CHMP).

Zytiga is a novel, once-daily, oral, androgen biosynthesis inhibitor, which when combined with prednisone or prednisolone, acts as a treatment for metastatic castration-resistant prostate cancer (mCRPC) in adult men whose disease has progressed on or after a docetaxel-based chemotherapy regimen.

Professor Karim Fizazi, Department of Cancer Medicine, Institute Gustave Roussy, France, commented that Zytiga "gives new hope to men who are suffering from this late stage of prostate cancer" and that it helps them "live longer with a better quality of life and less pain."

8th September 2011

Share

Featured jobs

Subscribe to our email news alerts

PMHub

Add my company
Digitas Health

Digitas Health is the only digital-at-the-core brand agency designed to connect today's healthcare brands with today's healthcare consumers and professionals....

Latest intelligence

Is telehealth delivering on its promises?
Using new digital technologies to help patients see their doctors online and not need to attend their surgery can help save time and money - but just how well is...
Channel purpose, change lives
GCI Health's Laura Starr on the power of creativity in health and wellness, all founded upon authentic brand purpose....
Wearables: the tangible product of the patient revolution
As the relationship between the patient and his doctor evolve, we look at how new technology is playing its part...

Infographics